On May 6, 2024, EyePoint Pharmaceuticals, Inc. announced the topline results from its Phase 2 PAVIA clinical trial for DURAVYU, a potential treatment for non-proliferative diabetic retinopathy (NPDR). The trial did not meet its pre-specified primary endpoint, but the company reported that DURAVYU was well tolerated and showed a reduction in NPDR progression at nine months. The full 12-month data is pending review to determine the future development path for DURAVYU in NPDR treatment. Concurrently, EyePoint Pharmaceuticals is preparing for the LUGANO trial, a pivotal study for wet age-related macular degeneration (AMD), set to begin in the second half of 2024. The company also announced an updated investor presentation on its website and plans to provide further clinical and regulatory updates...Show More

On May 6, 2024, EyePoint Pharmaceuticals, Inc. announced the topline results from its Phase 2 PAVIA clinical trial for DURAVYU, a potential treatment for non-proliferative diabetic retinopathy (NPDR). The trial did not meet its pre-specified primary endpoint, but the company reported that DURAVYU was well tolerated and showed a reduction in NPDR progression at nine months. The full 12-month data is pending review to determine the future development path for DURAVYU in NPDR treatment. Concurrently, EyePoint Pharmaceuticals is preparing for the LUGANO trial, a pivotal study for wet age-related macular degeneration (AMD), set to begin in the second half of 2024. The company also announced an updated investor presentation on its website and plans to provide further clinical and regulatory updates in the coming months. The PAVIA trial enrolled 77 patients and assessed the efficacy of DURAVYU, delivered via intravitreal injection, with the primary endpoint being improvement in DRSS levels at nine months. EyePoint Pharmaceuticals will host a conference call to discuss the results and has posted a press release and investor presentation as exhibits to the SEC filing.